arsenic trioxide has been researched along with Agnogenic Myeloid Metaplasia in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Fan, S; Li, WW; Mo, XD; Sui, XF; Wang, CL; Wang, FY; Xu, H | 1 |
Bai, Y; Dou, L; Li, D; Niu, J; Niu, X; Qin, L; Sun, K; Wei, S; Xiao, M; Zhang, L; Zhang, W; Zhou, P | 1 |
Advani, A; Bejanyan, N; Chan, J; Jankowska, A; Kalaycio, M; Maciejewski, JP; Mooney, L; Raza, A; Saunthararajah, Y; Sekeres, MA; Tiu, RV | 1 |
Chen, Y; Li, Z; Lu, Q | 1 |
2 review(s) available for arsenic trioxide and Agnogenic Myeloid Metaplasia
Article | Year |
---|---|
Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review.
Topics: Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis | 2022 |
Acute promyelocytic leukemia with myelofibrosis: A case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Primary Myelofibrosis; Treatment Outcome; Tretinoin | 2021 |
1 trial(s) available for arsenic trioxide and Agnogenic Myeloid Metaplasia
Article | Year |
---|---|
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Myelodysplastic-Myeloproliferative Diseases; Oxides; Primary Myelofibrosis; Thalidomide | 2012 |
1 other study(ies) available for arsenic trioxide and Agnogenic Myeloid Metaplasia
Article | Year |
---|---|
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Primary Myelofibrosis; Remission Induction; Survivors; Tretinoin | 2012 |